Boehringer Ingelheim has taken a major step forward in the global fight against avian influenza. The European Medicines Agency (EMA) has issued positive opinions recommending marketing authorisations under exceptional circumstances for two of the company’s latest vaccines:
Vaxxitek HVT+IBD+H5 and Vaxxinact H5.
Both vaccines target the H5 strain of avian influenza, which continues to trigger outbreaks across Europe and disrupt poultry production worldwide.
Avian influenza remains one of the most destructive diseases affecting both domestic and wild birds. The H5 strain, in particular, is:
Outbreaks often lead to:
With H5 outbreaks spreading to new regions—including Latin America and even Antarctica—there is an urgent need for modern, scalable prevention tools.
Boehringer Ingelheim’s two vaccines introduce innovative solutions to help national authorities strengthen disease control strategies.
Both vaccines are equipped with DIVA (Differentiate Infected from Vaccinated Animals) technology. This feature:
As H5 continues to mutate, vaccines must adapt as well. Boehringer’s products are built with continuous monitoring in mind, ensuring protection against emerging variants.
Armin Wiesler, head of the animal health business unit, emphasized the urgency of innovation in livestock health:
“Transboundary animal diseases like avian influenza will continue to be a threat. We are ready to support governments, health authorities and producers with our vaccines and expertise in designing strong disease control plans.”
Taoufik Rawi, head of poultry franchise, highlighted the importance of DIVA vaccines:
“The DIVA feature allows customers to run surveillance programmes and support safe trade while vaccinating. The positive EMA opinions are critical for strengthening preparedness across Europe.”
H5 outbreaks in recent years have:
The EMA’s positive opinions mark a critical milestone for Europe as it enhances its preparedness for ongoing and future outbreaks.
Following the EMA’s CVMP recommendation, the European Commission will review and decide on granting marketing authorisations under exceptional circumstances in the coming months.
If approved, these vaccines will provide policymakers and producers with new tools at a time when avian flu risks continue to escalate.
Boehringer Ingelheim is a global leader in both human and animal health. The company:
Their mission is built on a simple belief: the health of humans and animals is deeply connected.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!